This paper introduces DCFHP-alum, a ferritin-based COVID-19 vaccine formulated with aluminum hydroxide. The vaccine elicited potent and durable neutralizing antibodies in non-human primates against various SARS-CoV-2 variants, including Omicron, and even SARS-CoV-1. A booster dose given one year after the initial immunization produced a strong anamnestic response. The vaccine's stability at room temperature and potential for high-yield production suggest its suitability for global accessibility and use as a yearly booster or primary pediatric vaccine.
Publisher
Nature Communications
Published On
Apr 17, 2023
Authors
Payton A.-B. Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, Shaogen Tang, Prabhu S. Arunchalam, Mengyun Hu, Ozan S. Kumru, Mary Kate Morris, Jane Fontenot, Lisa Shirreff, Jonathan Do, Ya-Chen Cheng, Gayathri Vasudevan, Mark B. Feinberg, Francois J. Villinger, Carl Hanson, Sangeeta B. Joshi, David B. Volkin, Bali Pulendran, Peter S. Kim
Tags
COVID-19 vaccine
aluminum hydroxide
neutralizing antibodies
SARS-CoV-2
vaccine stability
high-yield production
pediatric vaccine
Related Publications
Explore these studies to deepen your understanding of the subject.